From 1 to 3 December 2023, the European Society for Medical Oncology Asia (ESMO Asia) Congress will be held in Singapore. At this congress, Henlius will share the latest results of clinical trials of several products, including anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab), HLX208 (BRAFV600E small molecule inhibitor), HLX07 (anti-EGFR mAb), and HLX26 (anti-LAG-3 mAb).
Notable among them is the updated analysis of HLX208-LCH/ECD201 study, the phase 2 study of HLX208 in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harbouring BRAFV600E mutation led by Professor Jian Li from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, and the results from this updated analysis were selected for a mini oral presentation. Moreover, results from the Asian subgroup of the pivotal phase 3 study (ASTRUM-004) of serplulimab in treating squamous non-small cell lung cancer (sqNSCLC) led by Professor Caicun Zhou from Shanghai Pulmonary Hospital, will be presented in the form of a poster presentation. Results of the final analysis of ASTRUM-004 were orally presented at the IASLC 2023 World Conference on Lung Cancer (WCLC 2023). Previously in 2022, the new drug application (NDA) of serplulimab for the treatment of sqNSCLC has been approved by the National Medical Products Administration (NMPA) based on the results of ASTRUM-004. The company will also present data from four other clinical studies in poster presentations.
In the future, Henlius will keep focusing on patient needs and inspire more "made-by-Henlius" products with efficient and innovative in-house capabilities, aiming to provide higher quality solutions and services for patients worldwide.